Klaus
Elenius
Professor, Institute of Biomedicine
Director, BioCity Turku
Turku Bioscience Centre
MD, PhD, professor
Research
ACTIONABLE RECEPTOR TYROSINE KINASE SIGNALING
Our goal is to understand how receptor tyrosine kinases (RTK) regulate the pathogenesis of human diseases, such as cancer. This information is needed for the development of molecularly targeted therapies. To recognize aberrations of RTK signaling in diseased tissue our laboratory also works on the molecular mechanism by which RTKs control normal processes, such as embryonic development. The work mainly focuses on the ErbB family of RTKs. Our laboratory has contributed to the field by e.g. by characterizing novel RTK signaling mechanisms, by identifying novel ErbB4 isoforms, and by determining the role of ErbBs and their ligands in angiogenesis.
Current topics
- Screens for predictive RTK mutations
- Novel RTK signaling mechanisms
- Development of preclinical models for development novel RTK inhibitors
- Sequencing of RTK inhibitor drug administration with cytotoxic agents
- In vitro “basket trials” with ErbB inhibitor drugs
- RTK signaling in angiogenesis and cardiovascular diseases
- RTKs in pediatric malignancies
- Biological role of novel ErbB4 isoforms in diseases and development
Elenius Lab members
- Anne Jokilammi, PhD
- Elli Narvi, PhD
- Deepankar Chakroborty, MSc
- Juho Heliste, MD
- Marika Koivu, MSc
- Johannes Merilahti, MSc
- Veera Ojala, MSc
- Janne Nordberg, MD
- Fred Saarinen, MSc
- Katri Vaparanta, MSc
- Kaisa Aalto, BM
- Maria Helkkula, BM
- Matias Mäenpää, BM
- Peppi Kirjalainen, BM
- Jori Torkkila, BM
Publications
Trans-activating mutations of the pseudokinase ERBB3 (2024)
Oncogene
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer (2024)
EMBO Molecular Medicine
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Immunomodulatory Synthetic Glycocluster Molecule Prevents Melanoma Growth in vivo (2024)
ChemBioChem
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
De Novo Multi-Omics Pathway Analysis Designed for Prior Data Independent Inference of Cell Signaling Pathways (2024)
Molecular and Cellular Proteomics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
STAT5b is a key effector of NRG-1/ERBB4-mediated myocardial growth (2023)
EMBO Reports
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations (2022)
Cancer Research Communications
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
An extracellular receptor tyrosine kinase motif orchestrating intracellular STAT activation (2022)
Nature Communications
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Combined genetic and chemical screens indicate protective potential for EGFR inhibition to cardiomyocytes under hypoxia (2021)
Scientific Reports
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
The impact of non-additive genetic associations on age-related complex diseases (2021)
Nature Communications
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices (2021)
Nature Communications
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))